#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Precursor T-lymphoblastic lymphoma/leukaemia recurrent Osteopetrosis Primary hyperoxaluria Astrocytoma Synovial sarcoma recurrent Malformation venous Follicular lymphoma stage III Neurofibroma Familial amyotrophic lateral sclerosis Small cell lung cancer extensive stage Duchenne muscular dystrophy Autologous haematopoietic stem cell transplant Cortical dysplasia Skin cancer Cystic fibrosis lung More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis – Trials in Disease Mantle cell lymphoma refractory – Basic Information Hereditary neuropathic amyloidosis – Basic Information Optic glioma – Life with Disease Breast angiosarcoma metastatic Lymphangiosarcoma Tuberous sclerosis complex – Trials in Disease Angiosarcoma recurrent – Life with Disease Netherton’s syndrome – Treatment Burkitt’s lymphoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tinengotinib Obinutuzumab Agrostis Stolonifera Pollen Riboflavin Sodium Phosphate Aficamten Nirmatrelvir Ustekinumab Piperacillin Monohydrate Doxecitine Empagliflozin Plerixafor H2-Receptor Antagonists Onasemnogene Abeparvovec Atenolol BRENSOCATIB Decitabine Metoprolol Mirtazapine Dulaglutide Ibrexafungerp More therapies…

    Learn about Your Condition

    Periodontitis Choroidal dystrophy Infertility female Cardiac valve disease Lipid metabolism disorder Small intestine leiomyosarcoma Dent's disease Adenocarcinoma of colon Aplasia pure red cell Duchenne muscular dystrophy Myopia Hyperplasia adrenal Urethral stenosis T-cell lymphoma Retinopathy of prematurity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Muhkxw Zgtkblwh Kzmrf 2sk Dixnseoyo 4lojy Hkpsrmo

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Adagrasib
    Croatia France Greece Hungary Italy The Netherlands +3

  • Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine
    • Olaparib
    France Germany Hungary Ireland Poland Spain

  • Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Greece Hungary Italy Poland Romania +2
Previous Page
1 … 50 51 52

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!